Market News AIOpen the app

Several financial firms kept their 'Buy' ratings for Candel Therapeutics and changed price targets to between $11 and $19.

OpinionRead the original at moomoo.com
Good for CADL

Candel's covered firms all kept Buy ratings, supporting a favorable reading of analyst views. They adjusted targets to $11–$19 per share, but the report does not say whether targets rose or fell.

CADL · Candel Therapeutics

AI read · Good for CADL

The AI's read

The firms' shared Buy ratings keep their stated view of Candel positive. The report does not say whether the target changes were increases or cuts, so those changes do not show whether the firms became more or less positive.

Get alerts for CADL

Follow Candel Therapeutics (CADL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CADL
Free on the App Store and Google Play, or on the web.